Introduction
Testicular germ cell tumors (TGCTs) represent the most prevalent solid malignancy among young men, with seminoma being the most common histological subtype. While cisplatin-based chemotherapy is highly effective for most patients, approximately 30% of those with advanced disease develop resistance. For this subset, the clinical outlook is bleak: salvage therapies are often toxic and aggressive, yet the risk of cancer-related mortality remains as high as 50%. Currently, there is a critical lack of alternative therapeutic modalities beyond standard chemotherapy. This study addresses this gap by identifying immune-related biomarkers that predict patient outcomes and discovering targeted molecular compounds to improve survival.
Methods
The researchers employed a multi-stage "dry-lab to wet-lab" approach. Initially, transcriptomic data from the TCGA-TGCT and GTEx databases were analyzed to identify differentially expressed immune-related genes (IRGs). Weighted Gene Co-expression Network Analysis (WGCNA) was used to identify gene modules, followed by LASSO and Cox regression analyses to construct a three-gene prognostic signature comprising CTLA4, SNX17, and TMX1.
The signature's predictive power was validated using external cohorts (GSE99420 and GSE197778) and local clinical samples (38 seminoma cases). The immune landscape was mapped using CIBERSORT and TIDE to assess immune cell infiltration and potential responsiveness to immunotherapy. To identify therapeutic candidates, the team performed in silico drug screening using molecular docking (MOE software) and molecular dynamics simulations (Gromacs) against the three signature proteins. Finally, the efficacy of identified compounds—Rutin, ICG-001, and Doxorubicin—was validated through in vitro assays using the Tcam-2 cell line and in vivo nude mice xenograft models.
Key Insights and Results
The three-gene Immune-Related Prognostic Signature (IRPS) demonstrated exceptional predictive accuracy. The Area Under the Curve (AUC) for predicting 5-year progression-free survival (PFS) reached 0.943, significantly outperforming traditional clinical markers such as T-stage and lymphovascular invasion. Decision Curve Analysis (DCA) further confirmed that integrating the IRPS with clinical factors provides the highest net benefit for clinical decision-making.
The study revealed distinct roles for the signature genes:
- CTLA4 was identified as a protective factor in this context; higher expression correlated with improved survival and increased infiltration of gamma delta T cells, suggesting a complex role in the seminoma immune microenvironment.
- SNX17 and TMX1 acted as risk factors, where their upregulation was associated with memory B-cell exhaustion and higher relapse rates.
Crucially, the drug screening identified specific modulators that could potentially reverse these risk profiles:
- Rutin (an antioxidant) was found to upregulate the protective CTLA4.
- ICG-001 and Doxorubicin were shown to downregulate the risk-associated SNX17 and TMX1, respectively.
Experimental validation confirmed that these compounds significantly inhibit the proliferation, migration, and invasion of seminoma cells in vitro and result in significantly smaller tumor masses in animal models compared to control groups. Molecular dynamics simulations confirmed that these compounds form stable, low-energy bonds with their target proteins, suggesting high specificity.
Conclusion and Future Directions
This study establishes a robust three-gene immune-related signature that accurately predicts prognosis and immunotherapy response in testicular seminoma. By identifying Rutin, ICG-001, and Doxorubicin as potential targeted therapies, the research provides a promising foundation for treating cisplatin-resistant cases.
While the results are promising, the authors acknowledge that the local validation cohort was relatively small and that further testing across a broader range of seminoma models is needed. Additionally, while Doxorubicin is a known chemotherapy agent, the use of Rutin and ICG-001 specifically for seminoma requires rigorous clinical trials to determine optimal dosing and safety in human patients. Nonetheless, these findings offer a significant step toward personalized medicine for seminoma patients.
Summary updated